AZD2962
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AZD2962, covering 2026-03-02 to 2026-03-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) [Phase 1]